Fenretinide in Treating Patients With Recurrent Malignant Glioma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

September 25, 2000

Primary Completion Date

September 14, 2004

Study Completion Date

November 1, 2004

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

fenretinide

Trial Locations (11)

10021

Memorial Sloan-Kettering Cancer Center, New York

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

94143-0128

UCSF Cancer Center and Cancer Research Institute, San Francisco

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

02115

Dana-Farber Cancer Institute, Boston

48109-0752

University of Michigan Comprehensive Cancer Center, Ann Arbor

15213-3489

University of Pittsburgh Cancer Institute, Pittsburgh

75235-9154

Simmons Cancer Center - Dallas, Dallas

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

78284-7811

University of Texas Health Science Center at San Antonio, San Antonio

53792-6164

University of Wisconsin Comprehensive Cancer Center, Madison

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00006080 - Fenretinide in Treating Patients With Recurrent Malignant Glioma | Biotech Hunter | Biotech Hunter